Live Partner ProductResumeRx: Email Your Resume, Get Matched to Biopharma Jobs. AI-driven resume matching and application customization built specifically for life sciences. No portals, no forms—just email. Try it free for 7 days.Try ResumeRx at gxpsoft.ai →
← Back to Analysis
Daily Summary••By OpenBio News Team

Daily Bio News Summary — 2026-07-22: PCSK9 launch, $2.8B psychedelics pivot, sickle cell setback

Today's 49-article harvest covers Merck's oral PCSK9 launch, Lilly's $2.8B AtaiBeckley deal, Agios's sickle cell disappointment, FDA's PreCheck manufacturing pilot, and AstraZeneca's Wainua flop.

The 2026-07-22 daily biopharma news harvest produced 49 fresh articles across 9 source sites, with a thematic mix dominated by M&A and financings (~16 items), clinical readouts and regulatory actions (~15 items), and FDA pipeline news (~10 items). Source distribution: BioPharma Dive 16, BioSpace 7, Reuters Biopharma 14, MedCity News 9, Fierce Pharma 8, Endpoints News 8, Pharmaphorum 8, PR Newswire FDA 6, FDA Newsroom 6, STAT News 2, Fierce Biotech 6.

PCSK9 oral launch and the cardiovascular race

The clearest single-company story is Merck’s PCSK9 franchise. Three independent sources today cover the Lipfendra / enlicitide launch: FDA’s own press announcement (priority 6 source), BioPharma Dive’s pipeline write-up, and Reuters Biopharma’s coverage of the same approval, plus Pharmaphorum framing it from an MSD perspective. All four reach the same conclusion: the oral PCSK9 inhibitor has cleared FDA, and Novartis’s CEO publicly shrugged off the competitive threat to Leqvio in the same Q2 earnings cycle (Fierce Pharma). Today’s harvest captures that exchange.

Adjacent: Novartis is bullish enough on Leqvio that it is also pushing into China via a $1.5B ADC deal with Myricx (Fierce Biotech), explaining the deal as “following the science” rather than a China strategy shift (Endpoints News).

$2.8B psychedelics pivot and Lilly’s M&A streak

Eli Lilly’s $2.8B AtaiBeckley acquisition is the most-covered single deal of the day. Three sources — BioPharma Dive, MedCity News, and Pharmaphorum (the latter with a $3.8B figure, suggesting a different inclusion metric) — all carry the headline. J&J and AbbVie were also said to have looked at AtaiBeckley before Lilly moved (Endpoints News). Today’s framing puts Lilly’s M&A count at ~12 deals in 2026. Separately, Jupiter Neurosciences entered the psychedelics space with a $100M MDMA deal (Fierce Biotech), suggesting the broader field continues to draw capital.

Clinical wins and losses

Setbacks: Agios’s sickle cell program is now officially dead across three outlets (BioSpace, BioPharma Dive, Fierce Biotech, MedCity News) after Phase 2 tebapivat data disappointed. Celldex scrapped its prurigo nodularis antibody after a Phase 2 flop (Endpoints News). GSK shelved camlipixant — the cough drug it acquired in the $2B Bellus deal — with three sources (BioPharma Dive, MedCity News, Pharmaphorum) all carrying the news. AstraZeneca’s Wainua failed a key heart disease trial, with shares tumbling (Reuters Biopharma) and a follow-up BioSpace piece on the company’s narrowed $80B path.

Approvals and readouts: Gilead and Merck reported Phase 3 data backing a first weekly HIV pill (Fierce Pharma, Pharmaphorum). Sanofi published new Tzield competitor data in Type 1 diabetes (BioSpace). Celcuity’s Revtorpyk / gedatolisib gained FDA approval in HR+/HER2- PIK3CA-wild-type breast cancer (MedCity News). Kyverna is poised to be the first CAR-T filing in autoimmune disease (BioSpace). Vertex was the only bidder for Crinetics in what became the year’s second-highest M&A premium (Endpoints News).

GLP-1 litigation: Novo Nordisk sued Lilly over ‘deceptive’ GLP-1 ads comparing doses — covered by Endpoints News, BioPharma Dive, and Fierce Biotech, while MedCity News flagged that compounders maintain a firm grip on the GLP-1 market despite the FDA crackdown.

FDA regulatory actions and policy

FDA’s activity is well-represented today. Six FDA Newsroom press releases made the cut: the Jul 22 removal of outdated color additive authorizations (the only one same-day), the Jul 17 PCSK9 approval, the Jul 10 manufacturing registration rule proposal, the Jul 1 sickle cell gene therapy approval, the Jun 30 donor immune cell therapy for blood cancer (Orca Bio), and the Jun 29 PreCheck Pilot selections. Reuters Biopharma adds context: biotech experts want FDA drug reviews based on science, not politics (filed today), and Lilly/Regeneron were selected for the manufacturing review fast-track.

What this batch is NOT telling us

The day’s harvest is light on AI-bio coverage (only the BioPharma Dive “How well are AI-discovered drugs faring in the clinic?” piece and a Sanofi “AI data becomes sticking point” piece), quiet on IPO news (Latigo’s filing is the only new addition), and absent on AI-bio funding flows. We did not see any FDA advisory committee calendars or PDUFA decision previews today, and the day’s M&A coverage is concentrated in 3-5 deals (Repligen/BioLife $1.5B, Royalty Pharma’s $425M AstraZeneca ATTR slice, Samsung Biologics’ $1.8B PolyPeptide bid, Lilly’s $2.8B AtaiBeckley, Angelini Pharma’s $4.1B Catalyst close) without the broader tier-2 sweep that’s typical of Q3 opens.

Reading order

If you only have time for three items today: (1) the BioSpace piece on AstraZeneca’s narrowed path to its $80B goal, which frames the day’s Wainua flop in strategic context; (2) the Endpoints News piece on Vertex being the only Crinetics bidder, because the M&A premium math is the headline; (3) the MedCity News piece on Celcuity’s Revtorpyk approval, because it’s the only first-in-class approval in the batch.

For the deal-focused reader: Pharma’s biggest Lilly/AtaiBeckley coverage in MedCity News, BioPharma Dive’s Brisol Myers “AI factory” + Samsung/PolyPeptide roundup, and Reuters Biopharma’s Angelini Pharma $4.1B Catalyst close.

For the regulatory-focused reader: FDA’s own PCSK9 press release is the canonical source (priority 6); the Reuters Biopharma piece on biotech experts wanting science-based FDA reviews is the framing.

How to read the underlying articles

Every item in today’s harvest lives at ~/my-repos/openbionews.com/src/content/news/ with a frontmatter sourceUrl field that links to the original article. The sourceName field tags the source site, pubDate is the article’s publication date in YYYY-MM-DD form, and companyId (when present) points to the corresponding company profile in ~/my-repos/openbionews.com/src/content/companies/. Today’s harvest added 16 new company JSONs, including Crystalys Therapeutics, Kyverna Therapeutics, Latigo Biotherapeutics, Mentari, Phanes Therapeutics, Ashlins Pharma, Precision Neuroscience, Co-Diagnostics, Alembic Pharmaceuticals, Consano Bio, Phothera, Valion Bio, Lakewood-Amedex Biotherapeutics, Redwire, Arrowhead Pharmaceuticals, Repligen, and Celldex Therapeutics.

Today’s articles (49 items, with source and date)

  1. Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug (BioSpace, 2026-07-22)
  2. Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on (BioSpace, 2026-07-22)
  3. AI data becomes sticking point in biopharma dealmaking (BioSpace, 2026-07-22)
  4. Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts (BioSpace, 2026-07-22)
  5. FDA’s radical transparency policy for rejections runs into legal uncertainty (BioSpace, 2026-07-20)
  6. Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence (BioSpace, 2026-07-20)
  7. How Kyverna rode CAR T’s autoimmune wave to the FDA’s door (BioSpace, 2026-07-20)
  8. Summit updates ivonescimab survival data ahead of PDUFA (Fierce Pharma, 2026-07-22)
  9. Sanofi reprimanded for disparaging Pfizer’s RSV vaccine (Fierce Pharma, 2026-07-22)
  10. Investors, Amgen agree to resolve tax bill lawsuit for $74M (Fierce Pharma, 2026-07-21)
  11. Sanofi announces limited changes to its revamped executive team (Fierce Pharma, 2026-07-21)
  12. Alembic site hit with warning letter on patient consent concerns (Fierce Pharma, 2026-07-21)
  13. Lilly, BMS aerospace partner Redwire opens facility in Indiana (Fierce Pharma, 2026-07-21)
  14. Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth (Fierce Pharma, 2026-07-21)
  15. Gilead, Merck phase 3 data back first weekly HIV pill (Fierce Pharma, 2026-07-21)
  16. As Maui recovers from devastating fires, a study offers vision for new rural health model (STAT News, 2026-07-22)
  17. Congo’s Ebola outbreak has killed nearly 1,000 people (STAT News, 2026-07-22)
  18. Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer’s prevention (Endpoints News, 2026-07-22)
  19. Updated: Summit reports two-year survival data for Western patients, though context lacking (Endpoints News, 2026-07-22)
  20. The biotech recovery gathers speed in Q2 (Endpoints News, 2026-07-22)
  21. Mentari adds $200M to migraine mission; Royalty’s latest ATTR-CM deal (Endpoints News, 2026-07-22)
  22. For Novartis’ CEO, China deals aren’t a strategy shift — just where the science is (Endpoints News, 2026-07-21)
  23. Crystalys gets $130M to take Sobi-rivaling gout drug to market (Endpoints News, 2026-07-22)
  24. Celldex scraps antibody in itchy skin nodules after Phase 2 flop (Endpoints News, 2026-07-22)
  25. Vertex was only bidder for Crinetics in year’s second-highest M&A premium (Endpoints News, 2026-07-22)
  26. Novo sues Lilly over ‘deceptive’ ads comparing GLP-1 drug doses (Endpoints News, 2026-07-21)
  27. J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal (Endpoints News, 2026-07-21)
  28. FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in Food (FDA Newsroom, 2026-07-22)
  29. FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol (FDA Newsroom, 2026-07-17)
  30. FDA Proposes Rule to Modernize Drug Manufacturing Registration (FDA Newsroom, 2026-07-10)
  31. FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease (FDA Newsroom, 2026-07-01)
  32. FDA Approves New Treatment That Uses Donor Immune Cells (Orca Bio, FDA Newsroom, 2026-06-30)
  33. FDA Selects Seven Participants for PreCheck Pilot Program (FDA Newsroom, 2026-06-29)
  34. Thiel-backed CEO eyes $50M fundraise after bagging China drug (Fierce Biotech, 2026-07-22)
  35. Royalty pens $425M deal for slice of AstraZeneca ATTR drug sales (Fierce Biotech, 2026-07-22)
  36. Crystalys mines $130M series B to push gout drug through phase 3 (Fierce Biotech, 2026-07-22)
  37. Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal (Fierce Biotech, 2026-07-21)
  38. Jupiter enters psychedelics space with $100M deal for MDMA drug (Fierce Biotech, 2026-07-21)
  39. Agios says adios to sickle cell program over lackluster Phase 2 data (Fierce Biotech, 2026-07-21)
  40. Lupin seeds US spinout with cash, clinical-stage cancer assets (Fierce Biotech, 2026-07-21)
  41. Kaken details the data behind its PI3K inhibitor filing (Pharmaphorum, 2026-07-22)
  42. Precision Neuro breaks new ground in BCI technology (Pharmaphorum, 2026-07-22)
  43. Gilead, MSD share data on once-weekly oral HIV treatment (Pharmaphorum, 2026-07-22)
  44. Novo’s Wegovy pill cleared for weight loss in EU (Pharmaphorum, 2026-07-22)
  45. Lilly buys into psychedelics with $3.8bn AtaiBeckley deal (Pharmaphorum, 2026-07-22)
  46. Bayer’s Kerendia on course for NHS use in heart failure (Pharmaphorum, 2026-07-22)
  47. MSD gets first FDA okay for oral PCSK9 cholesterol drug (Pharmaphorum, 2026-07-22)
  48. GSK abandons cough drug added in $2bn Bellus deal (Pharmaphorum, 2026-07-22)
  49. Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data (PR Newswire FDA, 2026-07-22)
#Daily Summary#BioSpace#Fierce Pharma#Endpoints News#FDA Newsroom#BioPharma Dive#MedCity News#Reuters Biopharma#Pharmaphorum#PR Newswire FDA#PCSK9#Psychedelics#FDA